EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID‐19 Patients Receiving Antivirals

Yuan Gao iD, Yixi Dong, Qiushi Bu, Zhijie Gong, Wei Wang, Zhongkai Zhou, Yunyi Gao, Liwei Liu, Menghua Wu, Jiaying Zhang, Lianchun Liang, Hongjun Li und 5 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Yuan Gao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antiviral Agents, Ritonavir, Artificial Intelligence, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: High-Level Public Health Technology Talent Project, Construction Project of High-level Technology Talents in Public Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID‐19 hospitalized patients.

Methods

A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated with nirmatrelvir/ritonavir or azvudine. The study employed a tripartite analysis—viral dynamics, survival curve analysis, and AI‐based radiological analysis of pulmonary CT images—aiming to assess the severity of pneumonia.

Results

Of 370 patients treated with either nirmatrelvir/ritonavir or azvudine as monotherapy, those in the nirmatrelvir/ritonavir group experienced faster viral clearance than those treated with azvudine (5.4 days vs. 8.4 days, p < 0.001). No significant differences were observed in the survival curves between the two drug groups. AI‐based radiological analysis revealed that patients in the nirmatrelvir group had more severe pneumonia conditions (infection ratio is 11.1 vs. 5.35, p = 0.007). Patients with an infection ratio higher than 9.2 had nearly three times the mortality rate compared to those with an infection ratio lower than 9.2.

Conclusions

Our study suggests that in real‐world studies regarding hospitalized patients with COVID‐19 pneumonia, the antiviral effect of nirmatrelvir/ritonavir is significantly superior to azvudine, but the choice of antiviral agents is not necessarily linked to clinical outcomes; the severity of pneumonia at admission is the most important factor to determine prognosis. Additionally, our findings indicate that pulmonary AI imaging analysis can be a powerful tool for predicting patient prognosis and guiding clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsRitonavirArtificial IntelligenceCOVID-19SARS-CoV-2COVID-19 Drug TreatmentHumansMaleRetrospective StudiesFemaleMiddle AgedAgedTreatment OutcomeTomography, X-Ray ComputedHospitalizationAdultPandemicsDrug CombinationsLung

Stichwörter der Autor:innen

COVID‐19antiviralartificial intelligence imageviral dynamics

Substanzen

Antiviral AgentsRitonavirDrug Combinations

Autor:innen und Institutionen

  • Fourth Department of Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing, China.
  • School of Management, University of Science and Technology of China, Hefei, China.
  • Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China.
  • Department of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • School of Basic Medicine, Qingdao University, Qingdao, China.
  • Department of Urology, Beijing You'An Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Yuan Gao

Förderung

  • High-Level Public Health Technology Talent Project
  • Construction Project of High-level Technology Talents in Public Health

Zitieren

APA

Gao, Y., Dong, Y., Bu, Q., Gong, Z., Wang, W., Zhou, Z., Gao, Y., Liu, L., Wu, M., Zhang, J., Liang, L., Li, H., Jiang, M., Luo, Z., Ma, Y., Zhang, X., & Hu, Z. (2024). Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID‐19 Patients Receiving Antivirals. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70006

Vancouver

Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, et al. Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID‐19 Patients Receiving Antivirals. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70006

BibTeX
@article{Gao2024,
  author = {Gao, Yuan and Dong, Yixi and Bu, Qiushi and Gong, Zhijie and Wang, Wei and Zhou, Zhongkai and Gao, Yunyi and Liu, Liwei and Wu, Menghua and Zhang, Jiaying and Liang, Lianchun and Li, Hongjun and Jiang, Mengxi and Luo, Zujin and Ma, Yingmin and Zhang, Xinyu and Hu, Zhongjie},
  title = {Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID‐19 Patients Receiving Antivirals},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70006}
}
Kostenlos starten →